Skip to main content
SpringerLink
Log in

An aggressive functioning pituitary adenoma treated with peptide receptor radionuclide therapy

  • Image of the Month
  • Published:
European Journal of Nuclear Medicine and Molecular Imaging Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Komor J, Reubi JC, Christ ER. Peptide receptor radionuclide therapy in a patient with disabling non-functioning pituitary adenoma. Pituitary. 2014;17:227–31.

    Article  Google Scholar 

  2. Maclean J, Aldridge M, Bomanji J, Short S, Fersht N. Peptide receptor radionuclide therapy for aggressive atypical pituitary adenoma/carcinoma: variable clinical response in preliminary evaluation. Pituitary. 2014;17:530–8.

    Article  CAS  Google Scholar 

  3. Baldari S, Ferrau F, Alafaci C, Herberg A, Granata F, Militano V, et al. First demonstration of the effectiveness of peptide receptor radionuclide therapy (PRRT) with 111In-DTPA-octreotide in a giant PRL-secreting pituitary adenoma resistant to conventional treatment. Pituitary. 2012;15(Suppl 1):S57–60.

    Article  Google Scholar 

  4. Dworakowska D., Grossman A. B. Aggressive and malignant pituitary tumours: state-of-the-art, Endocr Relat Cancer 2018.

    Google Scholar 

  5. Biousse V, Newman NJ, Oyesiku NM. Precipitating factors in pituitary apoplexy. J Neurol Neurosurg Psychiatry. 2001;71:542–5.

    Article  CAS  Google Scholar 

  6. Ghasemi M, Nabipour I, Omrani A, Alipour Z, Assadi M. Precision medicine and molecular imaging: new targeted approaches toward cancer therapeutic and diagnosis. Am J Nucl Med Mol Imaging. 2016;6:310–27.

    PubMed  PubMed Central  CAS  Google Scholar 

  7. Basu S, Alavi A. PET-based personalized management in clinical oncology: an unavoidable path for the foreseeable future. PET Clin. 2016;11:203–7.

    Article  Google Scholar 

  8. Choudhury P, Gupta M. Personalized & precision medicine in cancer: a theranostic approach. Curr Radiopharm. 2017;10:166–70.

    Article  CAS  Google Scholar 

  9. Teunissen JJ, Krenning EP, de Jong FH, de Rijke YB, Feelders RA, van Aken MO, et al. Effects of therapy with [177Lu-DOTA 0,Tyr 3]octreotate on endocrine function. Eur J Nucl Med Mol Imaging. 2009;36:1758–66.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. The Persian Gulf Nuclear Medicine Research Center , Department of Molecular Imaging and Radionuclide Therapy (MIRT), Bushehr Medical University Hospital, Faculty of Medicine, Bushehr University of Medical Sciences, Bushehr, Iran

    Majid Assadi, Hossein Shooli & Esmail Jafari

  2. Department of Neurology, Bushehr Medical University Hospital, Faculty of Medicine, Bushehr University of Medical Sciences, Bushehr, Iran

    Reza Nemati

  3. Department of Oncology, Bushehr Medical University Hospital, Faculty of Medicine, Bushehr University of Medical Sciences, Bushehr, Iran

    Seyed Javad Rekabpour

  4. Department of Internal Medicine (Division of Endocrinology), Bushehr Medical University Hospital, Faculty of Medicine, Bushehr University of Medical Sciences, Bushehr, Iran

    Iraj Nabipour

  5. Department of Radiology, Keck School of Medicine, University of Southern California, 1500 San Pablo Street, Los Angeles, CA, 90033, USA

    Ali Gholamrezanezhad

  6. Department of Cardiology, Bushehr Heart Medical Center, Faculty of Medicine, Bushehr University of Medical Sciences, Bushehr, Iran

    Abdullatif Amini

  7. Department of Nuclear Medicine, University Hospital Bonn, Sigmund-Freud-Str. 25, 53127, Bonn, Germany

    Hojjat Ahmadzadehfar

Authors
  1. Majid Assadi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Reza Nemati
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Hossein Shooli
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Seyed Javad Rekabpour
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Iraj Nabipour
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Esmail Jafari
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Ali Gholamrezanezhad
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Abdullatif Amini
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Hojjat Ahmadzadehfar
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Majid Assadi.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Patient consent

The patient was informed and signed a consent form.

Additional information

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This article is part of the Topical Collection on Image of the month

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Assadi, M., Nemati, R., Shooli, H. et al. An aggressive functioning pituitary adenoma treated with peptide receptor radionuclide therapy. Eur J Nucl Med Mol Imaging 47, 1015–1016 (2020). https://doi.org/10.1007/s00259-019-04578-z

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00259-019-04578-z

Search

Navigation